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Background: Canine chronic enteropathies (CE) are a group of intestinal diseases
that can be categorized based on treatment response into diet- or food- responsive
enteropathy (FRD), antibiotic-responsive enteropathy, steroid-responsive enteropathy,
and non-responsive enteropathy. CE can often be associated with intestinal dysbiosis
and thus administration of probiotic or synbiotic products may provide a useful tool for
the management of some of these patients. Enterococcus faecium (EF) is a probiotic
strain included in a commercially available synbiotic for small animals, however its impact
on the microbial communities in dogs with FRD has not yet been evaluated.
Hypothesis/Objectives: The administration of a synbiotic will lead to a significant
difference of the fecal microbial composition and/or diversity in dogs with FRD, and these
changes are not attributable to diet change alone.
Animals/Samples: Twelve dogs with FRD fed a hydrolyzed protein diet received either a
synbiotic (EF, fructooligosaccharides, gum Arabic) or placebo. Fecal samples were taken
before and 6 weeks into treatment. Fecal samples were also acquired from 8 healthy
dogs before and 6 weeks after being switched to the same hydrolyzed protein diet as
their sole food.
Methods: Bacterial DNA was extracted from fecal samples and next generation
sequencing based on the 16S rRNA genes was performed. Microbial composition and
diversity between groups were compared using QIIME.
Results: There was a small increase in species diversity in the feces of dogs with
FRD treated with synbiotics. However, there were no significant differences in microbial
community composition before and after 6 weeks in either the synbiotic or placebo
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treated dogs with FRD or the healthy dogs. In all groups, large individual variations
were observed.
Conclusions: No changes in microbial composition were observed in diseased or
healthy dogs with diet change alone. However, administration of a synbiotic increased
bacterial richness in both groups.
Keywords: Enterococcus, diarrhea, inflammatory bowel disease, probiotics, microbiome
INTRODUCTION
Canine chronic enteropathies (CE) are a group of intestinal
diseases of unknown cause (1, 2). They are usually classified
by response to treatment as food-responsive disease (FRD),
antibiotic-responsive disease (ARD), and steroid-responsive
disease (SRD), with the latter also being termed (idiopathic)
inflammatory bowel disease (IBD) (2, 3). All of these syndromes
manifest in variable degrees and combinations of gastrointestinal
signs (i.e., diarrhea, vomiting, weight loss, changes in appetite).
All dogs with CE present with intestinal inflammation to
some degree and have been shown to share similar alterations
in the microbiome when compared to healthy dogs (4). Those
alterations in the gut microbiome composition are termed
dysbiosis, especially when they result in functional changes in
the microbial transcriptome, proteome, or metabolome (5). It
has been speculated that oxygen, which is increased in the GI
tract of dogs with CE due to inflammation, might be responsible
for the observed dysbiosis (6). This hypothesis focuses on the
availability of oxygen in the intestinal lumen (5), which negatively
impacts strict anaerobe populations, and drives an uncontrolled
luminal expansion of facultative anaerobes, especially members
of the Enterobacteriaceae family (5). The increase in abundance of
facultative anaerobic bacteria belonging to the Enterobacteriaceae
family is a common marker of dysbiosis in dogs (7).
In dogs with IBD treated with immunosuppressive therapy,
with or without antibiotics or other therapeutic measures,
clinical recovery is not always accompanied by a recovery of
the microbial dysbiosis. In one study (8), although all dogs
clinically recovered, the diversity indices for the fecal bacterial
communities present after 3 weeks of therapy showed a trend
toward a further decrease.
Although antibiotics like metronidazole or tylosin are
prescribed to many dogs with chronic diarrhea, this practice is of
increasing concern. The true incidence of ARD is reported to be
low (8–16%) (9, 10), thus administering antibiotics empirically
likely leads to their overuse, directly or indirectly contributing
to global antimicrobial resistance. It is widely accepted that
antibiotic administration in general causes changes in the
composition and richness of the intestinal microbiota in people
(11) and companion animals (12), and this dysbiosis can be
detrimental for overall host health. Administration of oral tylosin
to healthy dogs was associated with microbiota alterations that
were still present 14 days after withdrawal (13), suggesting
a possible long-term adverse effect in some animals. Fecal
bacterial diversity was also reduced after oral administration of
metronidazole to healthy dogs (14). Overall, the necessity of
avoiding empirical and injudicious use of antibiotics in dogs with
chronic diarrhea cannot be overemphasized.
To aid recovery of dysbiosis in dogs with CE and as alternative
to antibiotic treatment (4–6), modification of the intestinal
microbiota in the form of pre- and probiotics (combinations of
both are called synbiotics) seems an interesting and desirable
treatment option. Several studies have shown that probiotics can
influence key biological signaling pathways of inflammation in
immune cells in humans and rodent models (7, 15–18), as well as
in dogs (19).
In one study, treatment of IBD in dogs with a probiotic
induced remission comparable with combined therapy
(immunosuppressive combined with antibiotic) (8). In addition,
when combined with immunosuppressive therapy, probiotics
were found to upregulate tight junction protein expression
in dogs with IBD, suggesting a beneficial effect on mucosal
homeostasis (19).
While dogs affected by FRD or IBD have similarly dysbiotic
microbiomes, their response to treatment can be somewhat
different. In one study, no significant changes in microbial
communities were found after treatment between dogs with FRD
treated with an elimination diet with a novel protein source
and dogs with IBD treated with a combination of diet and
immunosuppressant therapy (20). However, in another study
(21), the diversity of the fecal microbiome increased after feeding
a vegetable diet to dogs with FRD and after treatment the
fecal microbiome was no longer different from healthy controls.
The difference between these studies may be attributable to the
sampling schedule: in the first study (20), dogs where sampled
after 14 days, and in the latter (21), they were fed the vegetable
diet for 6 weeks before sampling. We have recently published
studies looking at the clinical effectiveness of Enterococcus
faecium (EF) in dogs with FRD, as well as assessing the influence
of this allegedly probiotic bacterium on several inflammatory
pathways in canine CE (22, 23). EF strain NCIMB 10415 4b1707
is widely available as a commercial small animal probiotic
or synbiotic in Europe and in the USA. So far, EF has not
convincingly shown a clinical benefit over dietary change alone
in FRD cases (23). However, the effect of EF on the composition
and diversity of the fecal microbiome of dogs with CE has not yet
been evaluated.
The hypothesis of the current study was that administration
of an E. faecium containing synbiotic product will lead to a
significant difference of the fecal microbial composition and/or
diversity in dogs with FRD, and these changes are not attributable
to diet change alone.
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MATERIALS AND METHODS
Animal Enrolment and Sample Collection
Dogs With Food-Responsive Chronic Enteropathy
The synbiotic clinical trial in dogs with FRD was conducted
between June 2010 and May 2013. Details of inclusion/exclusion
criteria and diagnostic workup as well as partial results of this
trial have been partially published elsewhere (22). The synbiotic
used (Synbiotic D-C; Probiotics International Ltd. [Protexin],
Somerset, UK) contained 1 × 109cfu EF strain NCIMB 10415
4b1707 per capsule, plus the prebiotics fructooligosaccharides
(FOS) and gum Arabic. The placebo consisted of an identical
capsule containing maltodextrin. A commercially available
hydrolyzed protein diet (Purina Veterinary Diet canine HAHypo
Allergenic, Nestle/Purina, York, UK) was used as elimination diet
throughout the study period.
Spontaneously voided fecal samples from these dogs with FRD
were collected at the initial visit and approximately 6 weeks after
starting the diet and trial medication (synbiotic or placebo), to
which the dogs were randomized before the start of the study in
a double-blinded fashion.
Healthy Control Dogs
To further ensure that microbiota changes anticipated upon
additional synbiotic treatment in dogs with FRD were not due
to the diet change, a group of healthy control dogs were recruited
to assess the effect of diet change alone as part of an unrelated
study at LSU. This study was conducted between May and
September 2014. All dogs were student and staff-owned and
deemed healthy based on physical examination and a minimal
database, consisting of a complete blood count, serum chemistry
profile, and urine specific gravity. Exclusion criteria included a
history of digestive disease in the 12 months before recruitment.
All of those dogs were given a broad spectrum anthelminthic
(fenbendazole, 50 mg/kg PO once daily) for 3 days prior to
the study.
Fecal samples from these healthy dogs (n = 8) were collected
before and after 6 weeks of receiving the same hydrolyzed protein
diet as their sole food (all dogs were on different commercially
available dog foods before).
Fecal Sample Collection
All freshly voided fecal samples were frozen at −80◦ C
immediately after collection and shipped to the Gastrointestinal
Laboratory at Texas A&M University on dry ice as a batch.
Microbiota Analysis
Bacterial DNA extraction from fecal samples was performed
using a commercially available kit (Power Soil R© DNA isolation
kit, Mo Bio Laboratories Inc., Quiagen, Carlsbad, CA, USA)
according to the manufacturer’s instructions and as described
elsewhere (18). Bacterial tag-encoded FLX-titanium amplicon
pyrosequencing (bTEFAP) based on the V1–V3 region (E.
coli position 27–519) of the 16 S rRNA gene was performed
on samples from dogs with FRD as described previously,
with forward primer 28F: GAGTTTGATCNTGGCTCAG and
reverse primer 519R: GTNTTACNGCGGCKGCTG (5, 24). Raw
sequence data were screened, trimmed, denoised, filtered, and
chimera depleted with the QIIME (Quantitative Insights Into
Microbial Ecology, www.qiime.org) pipeline version 1.7 with
similar settings as published previously (5, 24). Operational
taxonomic units (OTUs) were defined as sequences with at least
97% similarity using QIIME.
Healthy control dogs receiving the hydrolyzed protein
diet alone were part of a subset of an unrelated study
and conducted at a later time. For these samples,
Illumina sequencing was performed with the following
primers: 515F (GTGCCAGCMGCCGCGGTAA) and 806R
(GGACTACVSGGGTATCTAAT). Raw sequence data was
similarly screened, trimmed, denoised, filtered, and chimera
depleted with the QIIME pipeline version 1.9, similar to the
pipeline described above for dogs with FRD.
Analysis of sequencing data was done for all samples before
and after 6 weeks of dietary and/or synbiotic intervention. A
combined analysis with all 3 subgroups of dogs (FRD on diet
and synbiotic, FRD on diet and placebo, healthy dogs with
diet change) was not performed due to the different sequencing
primers used.
Alpha (α) diversity was assessed as a measure of species
richness in all samples. The chao1, Shannon index and observed
species data were generated as described previously (4, 6) to
generate the α-rarefaction plots and data. The OTU table was
rarefied at 8,403 sequences/sample for samples of dogs with
FDR, and 19,000 sequences for sample for the HC samples.
Phylogeny-based UniFrac distance metric analysis was used to
investigate differences in microbial communities as a measure
of beta (β)- diversity. For this, the analysis of similarity
(ANOSIM) function in a statistical software package (PRIMER
6, PRIMER-E Ltd., Luton, UK) was used on the UniFrac
distance matrixes, both weighted and unweighted. Individual
bacterial abundances were assessed first for normality using the
Shapiro-Wilk Test and found to be non-parametric. Therefore,
a Wilcoxon rank-sum test was used for taxonomic analysis of
paired samples. p-values were adjusted for multiple comparisons
by the Benjamin & Hochberg FDR. Statistical significance
was set at p < 0.05.
Linear discriminant analysis effect size (LEfSe) was used
to elucidate bacterial taxa that were associated with each diet
trial. LEfSe was calculated using Calypso, a web-based software
package that allows mining and visualizing of microbiome-host
interactions (25).
RESULTS
Animals
A total of 12 dogs of various breeds diagnosed with chronic
enteropathy completed the randomized placebo-controlled
treatment trial as part of another study and received a full
standard workup (22). These dogs were newly diagnosed and all
received the same hydrolyzed complete dog food. They were only
included in the trial if they showed a full clinical response, and
hence were classified as food-responsive. Dog breeds included
Labrador Retrievers (n = 6), Golden Retrievers (n = 2), and
one dog each of the following breeds: Bracco Italiano, English
Setter, Miniature Schnauzer, and Standard Poodle. Six dogs were
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intact males, 2 dogs were castrated males, and 4 dogs were spayed
females. The median age was 40 months (range 12–84 months).
Seven dogs had been randomly assigned to receive the synbiotic
product and 5 to receive a placebo.
In addition, a total of 8 healthy dogs were recruited that
underwent dietary change to the same diet as the diseased
populations, which included mixed breeds (n = 3), Mastiff (n =
2) and one each of the following breeds: Bull Terrier, Dachshund,
and Hungarian Vizsla. Four dogs were castrated males, 2 intact
females and 2 spayed females. The median age of the healthy
controls was 42 months (range 24–72 months).
Microbiota Analysis
There was no difference in the overall microbiota taxonomic
composition (β-diversity, unweighted UniFrac) before and after
administration of the hydrolyzed protein diet with either placebo
or synbiotic in dogs with FRD (ANOSIM unweighted p >
0.071, see Figure 1A). However, when microbiota taxonomic
composition was evaluated together with taxa abundance
FIGURE 1 | Principal coordinate analysis of the fecal microbiota from dogs
with food-responsive chronic enteropathy. Beta diversity was calculated based
on unweighted UniFrac distances (A, p = 0.205) and weighted UniFrac
distances (B, p = 0.107).
(weighted UniFrac, see Figure 1B), there was a significant
difference between the two groups at baseline (p = 0.038), and
in the placebo group before and after treatment (p = 0.016).
No difference was found on β-diversity for healthy controls
fed the hydrolyzed protein diet for the same 6-weeks period
(ANOSIM unweighted p= 0.836; weighted p= 0.260). However,
it is important to note that there was a large inter-individual
variation between subjects, which can be appreciated in Figure 2.
While some dogs remained within the same quadrant after diet
change, others showed a larger variation, as indicated by the
length of the arrows. Bacterial richness (α-diversity) was found
to be significantly increased in the group of dogs with FRD
treated with diet and the synbiotic vs. the placebo-treated dogs
(see Figures 3, 4). Rarefaction curves are shown in Figure 3
and indicate that the rarefaction depth was appropriate for the
analysis. In Figure 4, α-diversity parameters Chao1, Shannon
Index, and Observed Species are significantly increased in dogs
with FRD treated with diet and synbiotic compared to baseline (p
= 0.016, 0.031, and 0.016, respectively). Despite visible difference
of baseline samples from the placebo and synbiotic groups in
Figures 3, 4, no significance was seen (Chao1 p = 0.432 and
Observed Species p = 0.343). Dogs from the healthy control
group receiving the hydrolyzed protein diet alone did not show
any variation on α-diversity parameters Chao1, Shannon Index,
and Observed Species (see Figures 4, 5, p = 0.920, 0.165, and
0.706, respectively).
Linear discriminant analysis effect size (LEfSe) found an
increase in the genus Enterococcus (family Enterococcaceae)
to be associated with samples from dogs with FDR receiving
the combination of the hydrolyzed protein diet and the
synbiotic (see Table 1). Samples of dogs with FRD receiving
FIGURE 2 | Principal coordinate analysis of the fecal microbiota from healthy
dogs switched to hydrolyzed protein diet. Colors are marking individual dogs.
Arrows indicate change from day 0 (before diet change) to 6 weeks after
diet change.
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treatment with hydrolyzed protein diet combined with placebo
instead were found to be associated with an increase in the
order Clostridia.
FIGURE 3 | Rarefaction plot of fecal bacterial species from dogs with
food-responsive chronic enteropathy. Data shown are from before and 6
weeks after a change to a hydrolyzed protein diet as a sole food,
supplemented with either a synbiotic or a placebo, and expressed by the
Chao 1 diversity index (Upper) and the number of observed bacterial
species (Lower).
Taxonomy analysis revealed no differences before and
after treatment in dogs with FRD receiving diet and a
synbiotic (see Supplementary Table 1). However, there was a
significant decrease in Actinobacteria and Bacteroidetes in the
group of dogs with FRD that did not receive the synbiotic
treatment (corrected p-value 0.031 for both phyla) after 6
weeks (see Supplementary Table 2). In the group of healthy
dogs receiving the hydrolyzed protein diet alone, diet change
had no significant effect on distribution of bacterial taxa (see
Supplementary Table 3).
DISCUSSION
The objective of the current study was to assess changes in fecal
microbiota upon administration of a synbiotic combined with
hydrolyzed protein diet in dogs with FRD compared to effects
of diet change alone. Interestingly, even though the microbiota
composition (β-diversity) was not significantly altered, bacterial
richness as indicated by species diversity (α-diversity) increased
with synbiotic treatment. This effect was not seen after switching
either FRD or healthy dogs to the hydrolyzed protein diet alone.
When associations were investigated with LEfSe, the only
bacterial taxa associated with treatment with the synbiotic was
genus Enterococcus. This finding is not unexpected, as the study
design did not include a washout period between the end
of the synbiotic administration and the collection of samples.
Samples from dogs receiving treatment with hydrolyzed protein
diet and placebo, instead, were associated with an increase
in the order Clostridiales. Many members of this order are
known to be depleted in dogs with FRD and those with other
chronic enteropathies (e.g., family Lachnospiraceae), and their
increasemay simply reflect a recovery from dysbiosis as described
elsewhere (21).
In dogs with FRD that did not receive the synbiotic
treatment there was a significant decrease in Actinobacteria and
Bacteroidetes after 6 weeks of treatment with the hydrolyzed
protein diet. The difference in those two phyla, however, is likely
FIGURE 4 | Species richness of fecal samples from dogs with food-responsive chronic enteropathy. Chao1, Shannon index and observed species before and after 6
weeks of treatment with hydrolyzed protein diet and synbiotics are shown.
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FIGURE 5 | Rarefaction plots of fecal bacterial species from healthy dogs.
Data shown are from before (red lines) and 6 weeks after (green lines) a
change to a hydrolyzed protein diet as a sole food, and expressed by the
Chao1 diversity index (upper panel) and the number of observed bacterial
species (lower panel).
of no clinical significance, as it is not mirrored in changes on the
levels of bacterial order, family, or genus. In the group receiving
synbiotic treatment combined with the hydrolyzed protein diet,
no significant changes were observed in any taxonomic level.
The lack of an effect of diet alone on the fecal microbiota
diversity and composition in the healthy dogs is not unexpected.
Even though other dietary factors have been shown to influence
microbiota in rodent models and people (26, 27), these might
need to be drastic (e.g., very high-fat or high protein diets).
In a study with a diet that included exclusively vegetable
proteins but maintained macronutrient composition within
typical “maintenance” complete dry dog food, no significant
changes were seen in abundance, or diversity of microbial
communities of healthy dogs (21). Those results are in
agreement with ours; and indicate that the protein source is not
necessarily an important factor for gut microbial communities
of healthy dogs. However, the same study (21) found that
dogs with FRD had a significant increase in alpha-diversity,
TABLE 1 | Linear Discriminant Analysis (LDA) of bacterial taxa from canine fecal
samples and their associations with synbiotic treatment.
Bacterial Taxa LDA Score
BEFORE SYNBIOTIC
Order Lactobacillales 5.01
AFTER SYNBIOTIC
Family Enterococcaceae 4.20
Genus Enterococcus 3.88
BEFORE PLACEBO
Class Flavobacteriia 4.84
Order Flavobacteriales 3.92
Family Flavobacteriaceae 4.03
Family Bacillaceae 3.52
Genus Geobacillus 3.61
Phylum Fusobacteria 5.24
Class Fusobacteria 4.84
Order Fusobacteriales 4.84
Family Fusobacteriaceae 4.80
Family Fusobacteriaceae, unidentified genus 4.71
Genus Fusobacterium 3.27
Family Fusobacteriaceae, genus J2-29 3.71
AFTER PLACEBO
Phylum Firmicutes 5.12
Class Clostridia 5.25
Order Clostridiales 5.23
Only LDA scores >3.5 are shown.
and microbial communities significantly changed both in
composition and abundance when fed the vegetable-protein diet.
Such alterations likely reflect the recovery of the microbiota
once the irritating antigen is removed, rather than an effect of
the diet itself.
Significant increases in fiber content have been shown to
alter the canine fecal microbiota in a previous study (28). The
hydrolyzed protein diet used in our study, however, had a
low fiber content, which was not different from a standard
“maintenance” complete dry dog food (around 2–4% drymatter),
and the amount of FOS included in the synbiotic was not enough
to significantly alter those percentages.
It is important to note that overall, amongst both healthy and
diseased dogs, there was a large individual variation observed in
microbiome parameters between the two time-points examined,
similar to reports for people. In addition, despite randomized
group assignation, dogs assigned to placebo or synbiotic groups
significantly clustered separately at baseline, which further
complicates the interpretation of our data (see Figure 1). It is
well-known that large inter- and intra-individual variations in the
intestinal and fecal microbiota occur (4, 5, 24, 27), which is also
a possible explanation for the lack of overall effect on microbiota
composition observed in this study. Hence it is possible that a
larger number of dogs needs to be studied to “tease out” subtle
changes of the microbiota that could be caused by administration
of synbiotics. However, changes observed were accompanied by
clinical recovery in both placebo and synbiotic groups and might
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still be meaningful to the individual host organism. However,
there is currently no accepted way to assess those types of effects,
which fall into the realm of personalized medicine, and it was not
the aim of the study presented here to assess such effects.
In general, it is accepted that microbial diversity decreases
in the chronically inflamed gut in both people and dogs (29–
31). Hence, being able to increase richness might be one of
the small measures that can be taken to counteract “dysbiosis”
and inflammation. However, it is currently unclear which
specific changes of microbial composition might improve clinical
outcome in dogs with CE, and the increase in microbial
species richness seen in the synbiotic-treated group can be of
questionable impact.
With regards to the synbiotic used in this study, it is possible
that more “aggressive” probiotic or synbiotic interventions
(i.e., more frequent administration, higher dosages, different or
multiple strains of probiotics, different types, and dosages of
prebiotics) are necessary to increase the magnitude of the effect
seen. Studies that demonstrated the benefit of probiotics alone (8)
or in combination with standard therapy (19) in dogs with IBD
administered at a dosage of 112–225 billion bacteria, including
7 different strains, for each 10Kg of body weight (8), or 450
billion of the same bacteria mixture for 10–20Kg of body weight.
In comparison, our study included only one strain of EF, at the
dosage of 1 billion bacteria per dog once daily, as recommended
by themanufacturer, and in compliance with the European Foods
Standard Agency (EFSA) regulation (EC) no 1,831/2,003, which
regulates the use of probiotic bacteria in animal species, including
dogs, and cats.
In addition, reversal of both microbial alterations and the
associated inflammatory abnormalities seems to be a slow
process, especially if influencing the microbiome by synbiotics
is the only measure and no additional drugs with strong anti-
inflammatory effects are used (8). It has been shown that despite
a decrease in clinical activity indices, there were no changes
in the fecal microbiota and serum metabolome after at least 3
weeks of treatment in dogs with IBD (31). This also fits with the
observation, that the EF strain used in the synbiotic preparation
did not lead to a difference in clinical improvement or anti-
inflammatory gene expression profile in the intestinal mucosa of
the same dog cohort within 6 weeks (22). It might therefore be
necessary to observe and reassess these dogs after longer periods
of treatment, where indicators of improvement of dysbiosis and
clinical signs are more readily noted.
While next generation sequencing is an excellent tool to assess
changes in bacterial phyla and genera in different populations of
dogs, one limitation in the current study is that samples from the
2 study groups were analyzed in different runs and with slightly
different techniques, which might have introduced variation.
Also, Illumina sequencing might not be the ideal tool to look
for more subtle changes of bacterial composition beyond phyla
and genera. Species of bacteria present in low abundances that
are either likely important for mucosal health [i.e., Lactobacillus,
Bifidobacterium, Faecalibacterium prausnitzii (5, 32)] or have a
potential pathogenic role (i.e., E.coli, Clostridium perfringens) are
very difficult to assess without also employing more sensitive
methods, for example qPCR (33).
Even though no significant changes in microbial composition
were observed in diseased or healthy dogs with diet change
alone, administration of a synbiotic increased bacterial richness
in both groups. The EF strain’s transient colonization might
hence have significantly affectedmucosal homeostasis as reported
elsewhere (19). In addition, interactions between different
bacterial taxa and even metabolites produced by them can
activate metabolic pathways both in the host and in other
bacterial species. Therefore, metabolomics approaches to chronic
intestinal diseases assessing for example short chain fatty acids
or an untargeted detection of metabolites might be more
informative and a good target for future studies as exemplified
by studies in humans (28).
CONCLUSION
Overall, the results of this study show a small increase in species
diversity in the feces of dogs with FRD treated with synbiotics.
While we cannot quantify how much of this effect was a by-
product of the administration of the probiotic itself, even small
changes in composition may significantly impact metabolite
production and, as consequence, intestinal health. Questions of
which probiotic or synbiotic at what dose is most appropriate
for the treatment of canine CE, and especially which parameters
are most likely to represent therapeutic and clinical success
remain open and the subject of further studies, however, pro-
or synbiotics should be considered when empirical treatment
trials are performed, especially as a substitute for potentially
detrimental antibiotic trials.
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